DK2086981T3 - Forbindelser til inhibering af mitoseprogression - Google Patents

Forbindelser til inhibering af mitoseprogression

Info

Publication number
DK2086981T3
DK2086981T3 DK07867449.6T DK07867449T DK2086981T3 DK 2086981 T3 DK2086981 T3 DK 2086981T3 DK 07867449 T DK07867449 T DK 07867449T DK 2086981 T3 DK2086981 T3 DK 2086981T3
Authority
DK
Denmark
Prior art keywords
compounds
inhibiting mitosis
mitosis progression
progression
inhibiting
Prior art date
Application number
DK07867449.6T
Other languages
Danish (da)
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2086981(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of DK2086981T3 publication Critical patent/DK2086981T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK07867449.6T 2006-11-16 2007-11-14 Forbindelser til inhibering af mitoseprogression DK2086981T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
DK2086981T3 true DK2086981T3 (da) 2012-08-06

Family

ID=39315133

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07867449.6T DK2086981T3 (da) 2006-11-16 2007-11-14 Forbindelser til inhibering af mitoseprogression
DK12153131.3T DK2497772T3 (en) 2006-11-16 2007-11-14 A compound for inhibiting mitotic progression

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12153131.3T DK2497772T3 (en) 2006-11-16 2007-11-14 A compound for inhibiting mitotic progression

Country Status (34)

Country Link
US (7) US8026246B2 (cg-RX-API-DMAC7.html)
EP (4) EP2086981B1 (cg-RX-API-DMAC7.html)
JP (3) JP5102839B2 (cg-RX-API-DMAC7.html)
KR (2) KR101110458B1 (cg-RX-API-DMAC7.html)
CN (2) CN101547924B (cg-RX-API-DMAC7.html)
AR (1) AR064246A1 (cg-RX-API-DMAC7.html)
AT (1) ATE556076T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007322046B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718803B8 (cg-RX-API-DMAC7.html)
CA (1) CA2669680C (cg-RX-API-DMAC7.html)
CL (1) CL2007003244A1 (cg-RX-API-DMAC7.html)
CR (3) CR10782A (cg-RX-API-DMAC7.html)
CY (1) CY1112828T1 (cg-RX-API-DMAC7.html)
DK (2) DK2086981T3 (cg-RX-API-DMAC7.html)
EA (1) EA015779B1 (cg-RX-API-DMAC7.html)
ES (3) ES2384123T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20125459B (cg-RX-API-DMAC7.html)
HR (2) HRP20120490T1 (cg-RX-API-DMAC7.html)
IL (1) IL198690A0 (cg-RX-API-DMAC7.html)
MA (1) MA30988B1 (cg-RX-API-DMAC7.html)
MX (3) MX348568B (cg-RX-API-DMAC7.html)
MY (1) MY153243A (cg-RX-API-DMAC7.html)
NO (1) NO343338B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ577042A (cg-RX-API-DMAC7.html)
PH (1) PH12012502057B1 (cg-RX-API-DMAC7.html)
PL (2) PL2086981T3 (cg-RX-API-DMAC7.html)
PT (2) PT2497772E (cg-RX-API-DMAC7.html)
RS (2) RS53788B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201503350TA (cg-RX-API-DMAC7.html)
SI (2) SI2086981T1 (cg-RX-API-DMAC7.html)
TW (1) TWI401255B (cg-RX-API-DMAC7.html)
UA (1) UA94129C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008063525A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903279B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005003951T4 (de) 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
EP2373657B1 (en) * 2008-12-05 2016-09-14 Millennium Pharmaceuticals, Inc. 5,7-dihydro-6h-pyrimido[5,4-d][1]benzazepin-6-thiones as plk inhibitors
RU2535032C2 (ru) * 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN104031049A (zh) * 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
JP5844358B2 (ja) * 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
UY34114A (es) * 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
JP6360881B2 (ja) * 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
CA2997784A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CN108349943A (zh) 2015-09-09 2018-07-31 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
JP7158023B2 (ja) 2016-03-15 2022-10-21 オリソン ヘノミクス エセ． アー． 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
US20250249019A1 (en) 2022-04-08 2025-08-07 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
CN119907671A (zh) 2022-06-30 2025-04-29 伊莱利利公司 Kras g12c抑制剂给药方案
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
SU1181547A3 (ru) 1979-02-07 1985-09-23 Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) Способ получени пиримидо-2-бензазепинов или их фармакологически совместимых кислотно-аддитивных солей (и его вариант)
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000506160A (ja) * 1996-03-08 2000-05-23 ゼネカ リミテッド 神経学的に活性な試剤としてのアゾロベンズアゼピン誘導体
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
JP3188482B2 (ja) * 1997-09-29 2001-07-16 明治製菓株式会社 三環性トリアゾロベンゾアゼピン誘導体およびその製造法並びに抗アレルギー剤
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
ATE403644T1 (de) 1999-12-06 2008-08-15 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
EP1345926B1 (en) * 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
HUP0401107A3 (en) 2001-08-09 2004-10-28 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles, their use process for their preparation and pharmaceutical compositions containing them
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
DE602005003951T4 (de) 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
SI2086981T1 (sl) 2012-12-31
ES2528793T3 (es) 2015-02-12
CN101547924A (zh) 2009-09-30
MX348568B (es) 2017-06-20
ES2384123T3 (es) 2012-06-29
KR101342014B1 (ko) 2013-12-19
TW200829589A (en) 2008-07-16
US8026246B2 (en) 2011-09-27
US9765076B2 (en) 2017-09-19
AR064246A1 (es) 2009-03-25
EP2497773A1 (en) 2012-09-12
US20210214361A1 (en) 2021-07-15
CA2669680A1 (en) 2008-05-29
EP2086981A1 (en) 2009-08-12
GEP20125459B (en) 2012-03-26
US9988384B2 (en) 2018-06-05
EP2497772A1 (en) 2012-09-12
KR20110113210A (ko) 2011-10-14
CR10782A (es) 2009-06-24
PH12012502057A1 (en) 2015-09-14
SI2497772T1 (sl) 2015-03-31
PL2497772T3 (pl) 2015-05-29
EP2497772B1 (en) 2014-10-29
HK1175777A1 (en) 2013-07-12
SG176443A1 (en) 2011-12-29
ATE556076T1 (de) 2012-05-15
CY1112828T1 (el) 2016-02-10
NZ597252A (en) 2013-06-28
US20110312943A1 (en) 2011-12-22
US20190031662A1 (en) 2019-01-31
MA30988B1 (fr) 2009-12-01
JP2010510215A (ja) 2010-04-02
ZA200903279B (en) 2010-07-28
RS53788B1 (sr) 2015-06-30
CL2007003244A1 (es) 2008-04-04
KR20090091173A (ko) 2009-08-26
WO2008063525A1 (en) 2008-05-29
EP2497773B1 (en) 2015-02-25
HRP20150047T1 (en) 2015-03-13
PT2497772E (pt) 2015-02-05
AU2007322046A1 (en) 2008-05-29
CR20140154A (es) 2014-07-23
US11958855B2 (en) 2024-04-16
US20110312942A1 (en) 2011-12-22
HK1134672A1 (en) 2010-05-07
US20150166545A1 (en) 2015-06-18
US10836766B2 (en) 2020-11-17
CN103483343A (zh) 2014-01-01
DK2497772T3 (en) 2015-01-19
AU2007322046B2 (en) 2012-04-05
KR101110458B1 (ko) 2012-03-13
NO343338B1 (no) 2019-02-04
BRPI0718803B8 (pt) 2021-05-25
JP5452811B2 (ja) 2014-03-26
PL2086981T3 (pl) 2012-09-28
NZ611898A (en) 2015-01-30
BRPI0718803B1 (pt) 2020-11-17
EA015779B1 (ru) 2011-12-30
MX343391B (es) 2016-11-04
CN103483343B (zh) 2016-06-01
NZ577042A (en) 2012-03-30
HRP20120490T1 (hr) 2012-07-31
CR20140544A (es) 2015-01-12
CA2669680C (en) 2012-04-10
SG10201503350TA (en) 2015-06-29
HK1217699A1 (en) 2017-01-20
IL198690A0 (en) 2010-02-17
EP2086981B1 (en) 2012-05-02
JP5102839B2 (ja) 2012-12-19
NO20091864L (no) 2009-06-15
EP2944639B1 (en) 2017-01-04
JP2012006965A (ja) 2012-01-12
RS52313B (sr) 2012-12-31
CN101547924B (zh) 2013-09-25
EA200970486A1 (ru) 2009-10-30
US20080167292A1 (en) 2008-07-10
ES2537451T3 (es) 2015-06-08
US20240400567A1 (en) 2024-12-05
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
JP2014055166A (ja) 2014-03-27
HK1175778A1 (en) 2013-07-12
BRPI0718803A2 (pt) 2013-12-03
EP2944639A1 (en) 2015-11-18
PH12012502057B1 (en) 2018-10-24
TWI401255B (zh) 2013-07-11
UA94129C2 (ru) 2011-04-11
MY153243A (en) 2015-01-29

Similar Documents

Publication Publication Date Title
DK2086981T3 (da) Forbindelser til inhibering af mitoseprogression
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
DK3178792T3 (da) Fremgangsmåde til aflejringshæmning
DK2068927T3 (da) Fremgangsmåder til reducering af eosinofilniveauer
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
DK1974807T3 (da) Fremgangsmåde til fjernelse af endokrint forstyrrende forbindelser
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0813500A2 (pt) Compostos antivirais
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
BRPI0821086A2 (pt) Compostos inseticidas
DK2001892T3 (da) Imidazolthiazolforbindelser til behandling af proliferative sygdomme
DK2035166T3 (da) Fremgangsmåde til fremstilling af beholdere
ATE524477T1 (de) Aziridinylepothilonverbindungen
BRPI0922880A2 (pt) compostos inibidores de quinase
DK2073636T3 (da) Fremgangsmåde til fremstilling af oxymorphon
BRPI0811264A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0809996A2 (pt) Compostos
DK2061746T3 (da) Fremgangsmåde til fremstilling af diestere
BRPI0720097A2 (pt) Compostos de fosfonato
BRPI0815181A2 (pt) Compostos
DK2214929T3 (da) Køretøj til håndtering af styrtgods
DK2387591T3 (da) Copolymer til inhibering af uorganiske aflejringer
BRPI0814613A2 (pt) Compostos